巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    虛擬市場

    BioVie

    BIVI
    2.830
    ▼0.110
    ▼3.74%
    概況消息
    最少15分鐘延遲，股票資訊由第三方資訊供應商提供
    ・BioVie - 延遲價格・最後更新於 20/05 12:15
    最高位
    2.840
    最低位
    2.830
    開市價
    --
    前收市價
    2.940
    成交量(千)
    0.33
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    70.70
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    19.100 - 2.520
    所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    BioVie
    證券代碼
    BIVI.US
    所屬板塊
    Biotechnology
    公司業務
    BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. The company recently acquired the assets of NeurMedix Inc including NE3107 that inhibits inflammatory activation of ERK and NFB.
    發行量
    24962373
    公司總部
    2120 Colorado Avenue, Suite 230
    公司網址
    http://www.biovieinc.com
    公司電郵
    info@biovieinc.com
    公司電話
    +1 312 283-5793

    最新發佈

    暫無內容

    關於

    BioVie(BIVI.US)所屬的行業板塊為Biotechnology。
    BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. The company recently acquired the assets of NeurMedix Inc including NE3107 that inhibits inflammatory activation of ERK and NFB.
    詳細公司背景可參考: http://www.biovieinc.com。